Eli Lilly (NYSE: LLY) and National Resilience will invest $750 million to expand U.S. drug manufacturing, creating approximately 400 high-skilled jobs in Ohio. Under the partnership, Resilience will manufacture Lilly's KwikPen devices used for diabetes and obesity treatments. The investment increases Lilly's total U.S. manufacturing commitments to more than $55 billion since 2020, reinforcing its strategy to expand domestic production capacity. Sector: Pharmaceuticals / Healthcare Key Highlights 💰 Lilly and Resilience to invest $750 million in U.S. manufacturing 🏭 Expansion will create 400 high-skilled jobs in Ohio 💉 Resilience will manufacture Lilly's KwikPen devices 🩺 Supports production of diabetes and obesity treatments 🇺🇸 Lilly's U.S. manufacturing commitments now exceed $55 billion since 2020 Why It Matters The investment strengthens Lilly's domestic manufacturing network, helping meet growing demand for diabetes and obesity therapies while boosting long-term production capacity and supply chain resilience in the United States. https://www.thinksabio.com/reports/isr/LLY